Navigation Links
Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
Date:1/6/2009

PARSIPPANY, N.J., Jan. 6 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, announced today that enrollment has been completed in two pivotal Phase III SIMPLE trials to evaluate the safety and efficacy of a single intraoperative administration of EXPAREL(TM) (DepoBupivacaine) for prolonged postoperative analgesia.

Results from the studies in hemorrhoidectomy and in total knee arthroplasty (TKA) are expected to provide the primary clinical data, in addition to extensive existing preclinical and clinical data, for a planned 2009 NDA filing under U.S. Food and Drug Administration 505 (b)(2) regulations.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070618/PACIRALOGO)

EXPAREL, a proprietary product from Pacira Pharmaceuticals, is a novel long-acting, sustained-release formulation of bupivacaine, a local anesthetic widely used for treating postoperative pain. EXPAREL is being studied in several different types of surgical procedures where postoperative pain management is especially problematic and where the need for prolonged analgesia with a single intraoperative administration can provide a significant improvement in pain relief -- especially during the first 72-hours following surgery -- while also minimizing the need for opioids. With improved prolonged postoperative pain management and a reduction in opioid consumption, Pacira believes patients treated with EXPAREL will experience better pain management and have fewer opioid-related side effects such as nausea and vomiting, and improved outcomes overall.

Recently, Pacira reported the results of a Phase II TKA study of EXPAREL at the International College of Surgeons meeting in Vienna, Austria. The data showed the new sustained-release analgesic significantly reduced postoperative pain, opioid
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015  Boston Scientific Corporation (NYSE: BSX ... momentum and long-term growth strategies at a meeting with ... City . President and Chief Executive Officer ... company has to bring forward meaningful innovation to transform ... deliver shareholder value. "We are focused ...
(Date:5/1/2015)... May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ... and commercialization of innovative therapies for the treatment of ... E. Morris , chief financial officer  will be participating ... are as follows: Mizuho Third Annual Healthcare ... Omni Berkshire Place, New York ...
(Date:4/30/2015)... , April 30, 2015 /PRNewswire/ - Pivotal ... pharmaceutical company with a focus on Omega-3 therapies ... its operational highlights and financial results for the ... amounts referenced herein are in Canadian dollars unless ... have been significant, with the right strategic partners ...
Breaking Medicine Technology:Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6
... Bristol-Myers Squibb Company,(NYSE: BMY ) today announced ... accepted, for filing and review, the supplemental biologics,license ... of,pediatric patients with juvenile idiopathic arthritis (JIA) who ... disease-modifying anti-rheumatic drugs,(DMARDs) such as methotrexate (MTX) or ...
... of a pilot study,published in the Nutrition Journal ... hyperactivity disorder (ADHD) can benefit,from daily supplementation of ... demonstrated that children who consumed between 8 and ... long chain omega-3 fatty acids found in,fish oil) ...
Cached Medicine Technology:ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review 2ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review 3ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review 4Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD 2
(Date:5/1/2015)... 2015 Pioneer Millworks, the largest reclaimed ... in their reclaimed wood products at the 27th annual ... Center in NYC this May. Their newest offerings, Vat ... anticipated texture and color to North America's platform for ... texture and color in the design world and we're ...
(Date:5/1/2015)... The Workgroup for Electronic Data Interchange ... use of health IT to create efficiencies in healthcare ... the United States Government Accountability Office (GAO) for a ... Medicare. The report, “ Potential Uses of Electronically Readable ... the public on Apr. 24, 2015 and examines the ...
(Date:5/1/2015)... NJ (PRWEB) May 01, 2015 Hope ... continued support of Hope For The Warriors® and military ... $20K to support Hope For The Warriors®, a national ... the family unit, and restoring hope for our service ... autograph signings, All American Ford collected and matched small ...
(Date:5/1/2015)... The Quail Creek Relay for Life Team raised ... the Quail Creek Relay team has raised almost $860,000. ... year, including their biggest event, January’s Dinner and Auction; an ... Quail Creek Relay for Life team was established to honor ... director, states, “I was hooked when I learned how the ...
(Date:5/1/2015)... 01, 2015 Digital technology and Wi-Fi-enabled ... women between prenatal appointments, a preliminary study ... small sample of low-risk pregnant women, will be presented ... University Medical Faculty Associates at the 2015 American Congress ... Meeting, May 2-6. The digital technology used was developed ...
Breaking Medicine News(10 mins):Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2Health News:Quail Creek Country Club’s Relay for Life Team Raised Over $89,000 for American Cancer Society 2Health News:Mobile Technology May Be Effective in Monitoring Pregnant Women Between Office Visits, Study Shows 2Health News:Mobile Technology May Be Effective in Monitoring Pregnant Women Between Office Visits, Study Shows 3
... Jenifer Goodwin HealthDay Reporter , MONDAY, Sept. 13 ... thimerosal, a mercury-laden preservative that used to be found in ... infants exposed to only a little thimerosal, new research finds. ... that vaccination raises their children,s risk for autism, the researchers ...
... Sept. 13 (HealthDay News) -- Women can be vulnerable ... pregnancy, part of a condition called preeclampsia. And ... predict which women are most prone to preeclampsia in ... approach relies on so-called "metabolic profiling" to track telltale ...
... tests of mental aging reveals a good news-bad news situation. ... with age, to varying degrees. The good news is the ... to a study published by the American Psychological Association. ... and what,s called crystallized intelligence decline at older ages," said ...
... describing a newly developed pharmacological inhibitor is providing detailed ... in multiple human malignancies regulates a known tumor suppressor. ... 14th issue of the journal Cancer Cell , ... Mitogen-activated protein kinases (MAPKs) are enzymes that regulate multiple ...
... - A protein crucial for the immune response appears to ... form of childhood leukemia called T-cell acute lymphoblastic leukemia (T-ALL). ... the study shows, opening a potential avenue to new drugs ... by Iannis Aifantis, PhD, associate professor of pathology and director ...
... states, the European Union and a number of ... to make robots capable of serving as adaptable, ... people. The research project, known as ALIAS, places ... feelings of loneliness and isolation, and increasing activities ...
Cached Medicine News:Health News:More Evidence That Vaccines Don't Cause Autism 2Health News:More Evidence That Vaccines Don't Cause Autism 3Health News:Test Might Spot Women at High Risk for Pregnancy Complication 2Health News:Test Might Spot Women at High Risk for Pregnancy Complication 3Health News:New study reconciles conflicting data on mental aging 2Health News:New study reconciles conflicting data on mental aging 3Health News:Selective inhibition of BMK1 suppresses tumor growth 2Health News:NYU Langone scientists find key pathway implicated in progression of childhood cancer 2Health News:European partnership funds research toward robot aides for the elderly 2Health News:European partnership funds research toward robot aides for the elderly 3
0.2 mm, 90o angled tip. Flat smooth handle with polished finish....
Excellent for manipulation of the intraocular lens in the capsular bag. The angled and curved shaft allows the instrument to reach across the implant and catch the optic/ haptic junction to facilitat...
Excellent during IOL insertion while pushing the trailing haptic into position. Gently curved shaft and round handle....
Straight shaft with 0.2 mm hour glass shape tip. Round knurled handle with dull finish. Manufactured in titanium....
Medicine Products: